|Bid||158.25 x 900|
|Ask||158.56 x 1400|
|Day's range||156.62 - 162.20|
|52-week range||117.08 - 418.00|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||3.10|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||02 Jun 2022|
|1y target est||N/A|
This isn't shaping up to be a banner week for BioNTech (NASDAQ: BNTX). The bellwether coronavirus stock took it on the chin Monday and was being similarly battered by investors Tuesday because of post-earnings analyst price target cuts. Following second-quarter results that disappointed many investors, several analysts recalibrated their takes on BioNTech stock Tuesday.
Novavax (NVAX) reports dismal results in second-quarter 2022. The stock dives in after-market trading after management slashes revenue guidance for 2022 by half.